PT1030842E - Inibidores da metaloproteinase - Google Patents

Inibidores da metaloproteinase

Info

Publication number
PT1030842E
PT1030842E PT97912351T PT97912351T PT1030842E PT 1030842 E PT1030842 E PT 1030842E PT 97912351 T PT97912351 T PT 97912351T PT 97912351 T PT97912351 T PT 97912351T PT 1030842 E PT1030842 E PT 1030842E
Authority
PT
Portugal
Prior art keywords
methoxysuccinamide
pyridin
isobutyl
propyl
hydroxy
Prior art date
Application number
PT97912351T
Other languages
English (en)
Inventor
Raymond Paul Beckett
Fionna Mitchell Martin
Mark Whittaker
Andrew Miller
Original Assignee
British Biotech Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Biotech Pharm filed Critical British Biotech Pharm
Publication of PT1030842E publication Critical patent/PT1030842E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Saccharide Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT97912351T 1997-11-13 1997-11-13 Inibidores da metaloproteinase PT1030842E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB1997/003132 WO1999025693A1 (en) 1997-11-13 1997-11-13 Metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
PT1030842E true PT1030842E (pt) 2003-07-31

Family

ID=10807699

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97912351T PT1030842E (pt) 1997-11-13 1997-11-13 Inibidores da metaloproteinase

Country Status (21)

Country Link
EP (1) EP1030842B1 (pt)
JP (1) JP2001523666A (pt)
KR (1) KR100485479B1 (pt)
AT (1) ATE236126T1 (pt)
AU (1) AU740420B2 (pt)
BR (1) BR9714934A (pt)
CA (1) CA2310593C (pt)
DE (1) DE69720554T2 (pt)
DK (1) DK1030842T3 (pt)
ES (1) ES2195122T3 (pt)
GB (1) GB2333524A (pt)
HU (1) HUP0002811A3 (pt)
IL (1) IL135210A0 (pt)
NO (1) NO315702B1 (pt)
NZ (1) NZ503642A (pt)
PL (1) PL189542B1 (pt)
PT (1) PT1030842E (pt)
RU (1) RU2198164C2 (pt)
TR (1) TR200001353T2 (pt)
TW (1) TW474919B (pt)
WO (1) WO1999025693A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0822186B1 (en) * 1994-01-20 2000-03-15 British Biotech Pharmaceuticals Limited L-tert-leucine-2-pyridylamide
AU2986295A (en) * 1995-07-19 1997-02-18 British Biotech Pharmaceuticals Limited N-(amino acid) substituted succinic acid amide derivatives as metalloproteinase inhibitors

Also Published As

Publication number Publication date
KR20010031879A (ko) 2001-04-16
HUP0002811A2 (hu) 2001-01-29
DK1030842T3 (da) 2003-07-28
AU740420B2 (en) 2001-11-01
DE69720554D1 (de) 2003-05-08
ATE236126T1 (de) 2003-04-15
KR100485479B1 (ko) 2005-04-27
IL135210A0 (en) 2001-05-20
JP2001523666A (ja) 2001-11-27
GB9816317D0 (en) 1998-09-23
DE69720554T2 (de) 2004-01-08
ES2195122T3 (es) 2003-12-01
NO20002480D0 (no) 2000-05-12
PL189542B1 (pl) 2005-08-31
AU4958497A (en) 1999-06-07
TW474919B (en) 2002-02-01
EP1030842B1 (en) 2003-04-02
WO1999025693A1 (en) 1999-05-27
TR200001353T2 (tr) 2000-10-23
HUP0002811A3 (en) 2002-11-28
NO20002480L (no) 2000-05-12
GB2333524A (en) 1999-07-28
RU2198164C2 (ru) 2003-02-10
CA2310593C (en) 2007-05-08
NO315702B1 (no) 2003-10-13
EP1030842A1 (en) 2000-08-30
BR9714934A (pt) 2000-10-03
PL340494A1 (en) 2001-02-12
CA2310593A1 (en) 1999-05-27
NZ503642A (en) 2001-10-26

Similar Documents

Publication Publication Date Title
ATE269089T1 (de) Verwendung von vitamin d derivaten zur verstärkung der wirkung von zytotoxischen stoffen
TR200101969T2 (tr) Enflamasyon tedavisi için sübstitüe edilmiş benzopiran analogları.
AR012172A2 (es) Composiciones farmaceuticas que comprenden analogos de lactacistina y uso de los mismos para la fabricacion de un medicamento
NZ501277A (en) -2(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
DK0934276T3 (da) Anthranilinsyrederivater som multiresistensmodulatorer
ATE161731T1 (de) Anwendung von nor- und homo-gallensäurederivaten als absorptienförderer für arzneimittel
NO943165D0 (no) Heterocykliske karbonsyrederivater som binder til retinoid-reseptorer (RAR)
DE69221290D1 (de) Auf aromatischen sulfonamiden basierende hydroxamsäurederivate
BR9809468A (pt) Formulações farmacêuticas contendo voriconazol
ES2156120T3 (es) Derivados arilamidicos.
MX9706605A (es) Derivados de indol como antagonistas de los aminoacidos exitadores.
RU94037246A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования разрушения хряща
ATE183192T1 (de) Neue colon-oder ilean-spezifische steroid derivate
ES2059755T3 (es) Derivados organicos de hidrazina para uso farmaceutico.
AR004688A1 (es) Derivados de la 5-0-desosaminil--6-o-metil-eritronolida a, su procedimiento de preparacion, compuestos intermediarios para su exclusivo uso en dichoprocedimiento para la preparacion de productos biologicamente activo
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
PT1030842E (pt) Inibidores da metaloproteinase
CA2438509A1 (en) Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria
EA200400096A1 (ru) Применение корриноидов при кожных заболеваниях
ITPD920145A1 (it) Uso terapeutico della fosforil-l-serina-n-acil-sfingosina
AU640647B2 (en) 3-butenamide derivatives
IT1255241B (it) Derivato di acido biliare e suo uso in terapia
FI860074A (fi) Oktahydroindolizinfoereningar anvaendbara som smaertstillande medel.
Peterson et al. Cholera toxin-induced PGE2 activity is reduced by chemical reaction with L-histidine
AR019664A1 (es) Composicion para el tratamiento de enfermedades del cartilago